AlphAIAlphAI — Financial news for AI agents
investing.comSEP 212 min read$NYXH

Nyxoah shares fall after CFO departure announcement

Nyxoah SA (NYXH) shares dropped 2% after-hours after CFO John Landry announced his departure in 2026. Loïc Moreau will serve as interim CFO. The company reaffirmed its 2026 guidance: €36M-€40M revenue, 60%-62% gross margin, and €99M-€102M operating expenses.

Original reporting
investing.com
Published Sep 21, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$NYXH
Neutral
medium confidence
Mentioned
$NYXH
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NYXHNeutralLow
01

Why it matters

Executive turnover announced after market close; shares fell 2% in after‑hours trading.

02

Market read

Primary news for NYXH; limited spillover to sector.

03

What to watch

Potential hidden cost synergies from interim CFO's prior experience at GSK.

Relevance 6/10Novelty 7/10Timing: after‑hours Monday

Background

Nyxoah SA is a Nasdaq‑listed med‑tech firm developing neuromodulation therapy for obstructive sleep apnea.

Company-level read

Ticker impact

$NYXHNeutralMedium confidence
Context

CFO John Landry will step down and interim CFO Loïc Moreau appointed; guidance reaffirmed.

Expected impact

Modest downside risk in near term, potential rebound if transition proceeds smoothly.

Evidence & confidence

Executive turnover is material but the company is small‑cap and guidance remains stable, limiting scale of price move.

Market effects

Sector

Minimal impact on broader med‑tech sector; CFO changes are firm‑specific.

Regional

Limited to NYXH investors; no broader regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

Despite leadership change, reaffirmed guidance could support a buy‑on‑dip view.

Key entities

  • person
    John Landry

    Outgoing CFO of Nyxoah.

  • person
    Loïc Moreau

    President International, appointed interim CFO.

Read at source← All news

Related articles

SEP 3
HighAI 9/10

Nyxoah stock surges as sleep apnea study hits endpoints

Nyxoah SA (NYXH) shares rose 11.9% after its ACCCESS U.S. study met primary safety and efficacy endpoints. The Genio system showed a 77.2% Apnea-Hypopnea Index responder rate and zero device-related serious adverse events. The company plans to submit a premarket approval supplement to the FDA for expanded indication.

investing.com2 min
AUG 5
$NYXHMed

Nyxoah SA (NYXH): Financial results for Q2 2026

Nyxoah SA (NYXH) furnished an SEC Form 6-K — earnings release. ​ Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 2026 over Q1 2026 Mont-Saint-Guibert, Belgium –

SEC EDGAR 6-K2 min
JUL 10
$NYXHMed

Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day

Nyxoah SA said its Genio U.S. launch is gaining traction, citing 262 trained surgeons, 123 ordering customers, and 427 patients in prior authorization. It reported early launched accounts reached 15% market share in six months and said reimbursement is stable, with CMS code changes not affecting coverage and prior authorization approvals at a 100% rate. Nyxoah reiterated 2026 revenue guidance of EUR 36m to EUR 40m and noted a preliminary cash balance of EUR 98m.

yahoo.com4 min
JUL 7
$NYXHMed

Nyxoah Announces Preliminary Results for the Second Quarter of 2026

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) reported preliminary, unaudited Q2 2026 results: global net revenue expected at ~€7.7m (+21% sequential) and U.S. net revenue ~€5.2m (+22%). U.S. metrics included 55 surgeons trained and 89 new accounts activated. CMS proposed 12% hospital and 15% ASC reimbursement increases for Genio. Cash/assets expected ~€97.8m; €36m–€40m full-year guidance.

manilatimes.net6 min